DNMT inhibitors and HDAC inhibitors regulate E-Cadherin and Bcl-2 expression in endometrial carcinoma in vitro and in vivo

Chemotherapy

Volumn 58, Issue 1, 2012, Pages 19-29

  Yi, Tie Zhong ^a   Li, Jia ^b   Han, Xu ^a   Guo, Jing ^c   Qu, Quanxin ^d   Guo, Lei ^e   Sun, Hai Di ^f   Tan, Wen Hua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c Obstetrics and Gynecology Department   (China)

^d TIANJIN FIRST CENTRAL HOSPITAL   (China)

^e Obstetrics and Gynecology Department   (China)

^f Harbin First Hospital   (China)

Author keywords

Bcl 2; DNA methyltransferase inhibitors; E cadherin; Endometrial cancer; Histone deacetylase inhibitors; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN BCL 2; UVOMORULIN; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CADHERINS; CARCINOMA; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; ENDOMETRIAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSPLANTATION, HETEROLOGOUS; VALPROIC ACID;

EID: 84862778645     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000333077     Document Type: Article

References (29)

1. Endometrial cancer: Http://www.cancer.gov/ cancertopics/types/ endometrial. National Cancer Institute. Accessed 2/9/2009.
2. Hubbard SA, Gargett CE: A cancer stem cell origin for human endometrial carcinoma? Reproduction 2010; 140: 23.
3. Flora Z, George B, Eftichia K, Marinos T, Nikitas N, Meletios AD, Christos A: Endometrial cancer: What is new in adjuvant and molecularly targeted therapy? Obstetrics Gynecol Int 2010; 2010.
4. Bansal N, Yendluri V, Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16: 8-13.
5. Noriyuki T, Hisashi N: Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet Gynecol Int 2010; 2010: 923824.
6. Samarnthai N, Hall K, Yeh IT: Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010; 2010;162363 (Epub).
7. Ellis L, Pili R: Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals 2010; 3: 2441-2469.
8. Tan J, Cang S, Ma Y, Petrillo RL, Liu D: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3: 5.
9. Cang S, Ma Y, Liu D: New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol 2009; 2: 22.
10. Cheung H, Lee T, Davis A, Taft D, Rennert O, Chan W: Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAS in human testicular cancer. Br J Cancer 2010; 102: 419-427.
11. Griffiths EA, Gore SD: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes, NIH Publ Access 2008; 45: 1-23.
12. Gravina GL, Festuccia C, Marampon F, Popov VM, Pestell RG, Zani BM, Tombolini V: Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer 2010; 9: 305.
13. Bender CM, Pao MM, Jones PA: Inhibition of DNA methylation by 5-aza-2-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res 1998; 58: 95.
14. Leblanc M, Poncelet C, Soriano D, Walker-Combrouze F, Madelenat P, Scoazec J, Darai E: Alteration of CD44 and cadherins expression: Possible association with augmented aggressiveness and invasiveness of endometrial carcinoma. Virchows Arch 2001; 438: 78-85.
15. Yi TZ, Guo J, Zhou L, Chen X, Mi RR, Qu QX, Zheng JH, Zhai L: Prognostic value of E-cadherin expression and CDH1 promoter methylation in patients with endometrial carcinoma. Cancer Invest 2011; 29: 86-92.
16. Balaram P, Alex S, Panikkar B, Rajalekshmi T: Adhesion related proteins E cadherin, P cadherin, CD44, and CD44v6, and antimetastatic protein nm23H1 in complete hydatidiform moles in relation to invasion potential. Int J Gynecol Cancer 2004; 14: 532-539.
17. Jia F, Figueroa SD, Gallazzi F, Balaji BS, Hannink M, Lever SZ, Hoffman TJ, Lewis MR: Molecular imaging of Bcl-2 expression in small lymphocytic lymphoma using 111 Inlabeled PNA-peptide conjugates. J Nucl Med 2008; 49: 430.
18. Zhou C, Li X, Du W, Feng Y, Kong X, Li Y, Xiao L, Zhang P: Antitumor effects of ginkgolic acid in human cancer cell occur via cell cycle arrest and decrease the Bcl-2/Bax ratio to induce apoptosis. Chemotherapy 2010; 56: 393-402.
19. Saha A, Kuzuhara T, Echigo N, Fujii A, Suganuma M, Fujiki H: Apoptosis of human lung cancer cells by curcumin mediated through up-regulation of 'growth arrest and DNA damage inducible genes 45 and 153'. Biol Pharm Bull 2010; 33: 1291-1299.
20. Liu H, Wang Z, Bai Y, Wang M, Li Y, Wei S, Zhou Q, Chen J: Different BAG-1 isoforms have distinct functions in modulating chemotherapeutic-induced apoptosis in breast cancer cells. Acta Pharmacol Sin 2009; 30: 235-241.
21. Liu SY, Song SX, Lin L, Liu X: Molecular mechanism of cell apoptosis by paclitaxel and pirarubicin in a human osteosarcoma cell line. Chemotherapy 2010; 56: 101-107.
22. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CPG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
23. Shao Y, Lu J, Cheng C, Cui L, Zhang G, Huang B: Reversible histone acetylation involved in transcriptional regulation of WT1 gene. Acta Biochim Biophys Sin (Shanghai) 2007; 39: 931-938.
24. Tyteca S, Legube G, Trouche D: To die or not to die: A HAT trick. Mol Cell 2006; 24: 807-808.
25. Shankar S, Srivastava RK: Histone deacetylase inhibitors: Mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-298.
26. Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999; 401: 188-193.
27. Ateeq B, Unterberger A, Szyf M, Rabbani SA: Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 2008; 10: 266-278.
28. Du H, Qi Y, Shi Y, Bu D, Wu S: Apoptosis and re-expression of p16 gene in the myeloma cell line U266 induced by synergy of histone deacetylase inhibitor and demethylating agent (in Chinese). Ai Zheng 2002; 21: 1057-1061.
29. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-107.